AUTHORS
Felicia Kemp, MA, Rebecca Brown, MD2, Lukas Murdych3, Archana Ramgopal, DO4, Gail Waltz5, Betsey Ann Varghese6, Manda Ramsey7, Brent Koehn8, Lisa Rose Mathews9, Aaron Yang10, Amanda Poholek, PhD11, Bruce Blazar, MD, PhD12, Heth Turnquist, PhD13, Craig Byersdorfer, MD, PhD14
AFFILIATIONS
1 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
7 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
10 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
11 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
12 University of Minnesota, Minneapolis, Minnesota, United States
13 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
14 University of Minnesota, Minneapolis, Minnesota, United States
ABSTRACT
Fatty acid oxidation (FAO) is upregulated in donor T cells following allogeneic transplantation, but the mechanism controlling these changes is unknown. Further, there was no clear approach to targeting this pathway therapeutically. Peroxisome proliferator-activated receptor delta (PPARδ) is a nuclear receptor and transcription factor that enhances the expression of multiple genes involved in FAO. To clarify a role for PPARδ during graft-versus-host disease (GVHD), donor T cells were tested on day 7 post-transplant for PPARδ by immunoblot, which showed a >3-fold increase in protein levels in allogeneic T cells (p<0.0001). Importantly, increases in FAO were also seen in human T cells during xenogeneic GVHD (p<0.0005), with a similar rise in PPARδ protein expression. To investigate the necessity of PPARδ during GVHD, wild-type (WT) and PPARδ knockout (KO) T cells were transplanted into B6D2F1 mice in a haploidentical transplant model. T cells lacking PPARδ caused less severe GVHD, with markedly higher survival rates (p<0.007) and a significant reduction in the total number of PPARδ KO CD4 donor T cells recovered on day 7 post-transplant (p=0.0046). In contrast, the number of recovered CD8 T cell numbers did not differ between donor genotypes. Supporting a role for PPARδ in driving FAO, bulk RNA sequencing of day 7 donor T cells identified downregulation of five genes known to be involved in fatty acid metabolism in PPARδ KO CD4 T cells. To assess this effect on post-transplant proliferation, in vivo 5-bromodeoxyuridine (BrdU) labeling was performed on day 5, which revealed significantly lower BrdU incorporation in CD4 KO T cells (p=0.0042); but no proliferative differences between WT and PPARδ KO CD8 cells. Importantly, proliferation was not broadly impaired with PPARδ deficiency, as PPARδ KO CD4 T cells were recovered in equivalent numbers following syngeneic transplantation, and CD8 KO cells outperformed their WT counterparts under these same conditions.
Hypothesizing that GVHD mitigation was primarily attributable to PPARδ deficiency within donor CD4 T cells, we transplanted CD4-enriched populations of WT and PPARδ KO donor T cells, to minimize alloreactive CD8 influence. Critically, 13 of 16 mice transplanted with PPARδ KO CD4 T cells were alive at the end of the study (day 84), with an associated improvement in both weight recovery and clinical scores. By comparison, only 3 of 16 of mice receiving WT cells were alive on day 84. These data suggested an early impairment of FAO, which then hampered CD4+ clonal expansion and the subsequent ability to cause severe GVHD. To garner support for this idea, we investigated donor T cell accumulation in the spleens, livers, and small intestines of recipients on day 21 post-transplant. Immunohistochemical analysis showed decreased accumulation of PPARδ KO CD3+ cells in recipient livers and spleens on day 21, as well as reduced numbers of PPARδ KO donor CD4+ T cells in both the liver (p=0.0309) and the lamina propria compartment of the small intestine (p=0.0070), as determined by flow cytometry.
Finally, we assessed the ability of pharmacological PPARδ inhibition to decrease GVHD severity. Transplanted mice received either vehicle control or oral GSK3787, an irreversible inhibitor of PPARδ, at 5 mg/kg on days 3, 7, 10, and 14. An additional cohort received oral GSK3787 along with donor T cells treated for 24 hours with 10 µM GSK3787 prior to transplantation (combination group). Day 15 analysis revealed a 65% reduction in CD4+ donor T cell accumulation in recipient livers for mice in the combination group, and a 47% reduction in donor CD4+ T cells in mice receiving oral GSK3787 alone. Together, these data clearly demonstrate that PPARδ protein levels increase in both murine and human donor T cells during GVHD, that PPARδ deficiency promotes a selective defect in CD4 T cells, involving both an early proliferation impairment along with a subsequent decrease in target organ accumulation, and that the effects of genetically ablating PPARδ can be recapitulated through administration of an irreversible pharmacologic inhibitor. Collectively, these results highlight the translational potential of targeting PPARδ as a novel strategy to mitigate GVHD.
DISCLOSURES
Felicia Kemp, MA: No relevant conflicts of interest to declare.